Clinical trial · no report yet · Phase 3
DURGA-6
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- NCT07735637 ↗
- Not yet recruiting
- AstraZeneca
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)
- Phase
- Phase 3
- Status
- Not yet recruiting
- Conditions
- Newly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- AZD0120; Cyclophosphamide; Fludarabine; Melphalan (part of ASCT); Lenalidomide
- Arms
- Arm A: AZD0120 · Experimental
- Arm B: Autologous Stem Cell Transplant (ASCT) · Active comparator
- Enrollment
- 750 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)
- Sponsor
- AstraZeneca
- Start
- Aug 25, 2026 (estimated)
- Primary completion
- Oct 11, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07735637 · updated Jul 30, 2026